Aurobindo's plan to take on Pfizer's Prevnar gathers momentum

Indian drugmaker Aurobindo is planning its first vaccine launch in 2018, and has the multibillion dollar pneumococcal conjugate vaccine (PCV) market firmly in its sights.

Aurobindo's just-published annual report reveals it has completed a pilot plant that is pushing out vaccine material for clinical trials, and is currently working on the production capacity to support the first commercial launches. 

"The plans are to create infrastructure for 50 million dosages per annum, with the first phase launch being targeted for 25 million doses," said Aurobindo, which is among the top five listed pharma companies in India.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

If successful, Aurobindo will enter a market dominated by Pfizer's Prevnar PCV franchise, which brought in $2.76 billion in the first 6 months of the year. At the moment Prevnar's only competition comes from GlaxoSmithKline's Synflorix vaccine, which brought in £228 million ($295 million) in the same period.

Sales of Pfizer's flagship vaccine were actually down slightly on the same period of 2015, suffering from comparison with strong demand last year for a new version of the product--Prevnar 13--with broader coverage against Streptococcus pneumoniae serotypes than both Prevnar and Synflorix.

Aurobindo entered the vaccines business via a joint venture with Tergene Biotech that was set up last year and, according to the partners, will make use of a quicker, cheaper vaccine manufacturing platform that could allow them to undercut the rival products.

PCV is the lead candidate in the partnership but the intention is to develop a "sizeable vaccines portfolio," according to Aurobindo, which holds a majority stake in the JV. The company did not respond to a request for comment on its vaccine plans.

Meanwhile, Aurobindo is trying to diversify its business beyond generic dosage forms and active pharmaceutical ingredients (API) and into higher-value specialised medicines. That includes not only vaccines but also "oncology, hormones, enzymes, peptides, depot injections, inhalers, nasal and dermatology products," it says.

A new plant for oral cancer and hormonal therapy formulations has been completed and is now in operation, while a unit for producing injectable cancer drugs is due to come online later this year. The company says it intends to file for approval of more than 15 cancer drugs in the coming year.

- read Aurobindo’s latest annual report

Related Articles:
Pfizer's superstar jab Prevnar 13 takes a hit in Q2
India's Aurobindo eyes Teva generics for divestment in Allergan deal
Pfizer's superselling Prevnar 13 jab wins expanded use in U.S.

Suggested Articles

Novartis is doing more portfolio pruning, offloading three endocrine drugs to Recordati.

Turns out, the FDA’s March rejection of Sanofi's Zynquista was just a preview of what would come for the SGLT class in Type 1 diabetes.

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down.